hrp0094p2-154 | Diabetes and insulin | ESPE2021

Neonatal Diabetes Secondary to Isolated Pancreatic Agenesis

Bakhamis Sarah , AlSagheir Afaf ,

Background: Pancreatic agenesis has been reported as a cause of neonatal diabetes. Most commonly it was associated with severe neurodevelopmental problems caused by homozygous mutations in the transcription factor PTF1A. Isolated pancreatic agenesis was related to biallelic mutations in an enhancer located near PTF1A gene, which suggests that the enhancer is tissue specific to the pancreas. PDX1 is another transcription factor gene in which biallelic mutation ...

hrp0097p2-24 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Familial growth hormone deficiency associated with a PROKR2 gene variant

El Hattab Ayman , Ehtisham Sarah

A 16 year old boy initially presented with short stature at age 6, with height <0.4th centile (HSDS -2.78). Bone age was 1.9 years delayed, and growth hormone deficiency was diagnosed after 2 stimulation tests. The rest of his pituitary function was normal. He never had pituitary imaging. Growth hormone treatment was started, and he had an excellent growth response with HSDS improving to -1.57 by 10 years. The growth hormone treatment was discontinued when the family reloca...

hrp0092p3-258 | Thyroid | ESPE2019

The Challenge to Treat Neonatal Autoimmune Hyperthyroidism in a Small Preterm

Lignitz Sarah , Coors Detlef , Pohlenz Joachim

Background: The prevalence of hyperthyroidism in pregnancy is about 0.2%, mostly due to Graves disease. Neonatal autoimmune hyperthyroidism caused by the transplacental passage of stimulatory thyrotropin receptor antibodies (TRAB) of the IgG class is a rare disorder. It occurs in only 2% of the neonates of mothers with Graves disease, is transient and associated with high morbidity and mortality rates up to 25%. Antithyroid drugs are the treatment ...

hrp0082p1-d2-28 | Autoimmune Endocrine Disease | ESPE2014

Immune Changes are Observed After Radioiodine Treatment for Hyperthyroidism in Graves’ Disease Patients

Cote-Bigras Sarah , Verreault Jean , Rottembourg Diane

Background: GravesÂ’ disease (GD) involves autoimmunity against TSH receptor (TSHR) bearing cells, leading to hyperthyroidism and often orbitopathy. When hyperthyroidism is treated with radioactive iodine (RAI), exacerbation of the orbital disease can occur.Objective and hypotheses: We hypothesized that RAI has immune effects affecting the balance between auto-reactive T cells and T cells with regulatory properties.Method: We m...

hrp0084p3-1178 | Thyroid | ESPE2015

Short Stature with Lipodystrophy: Reminder of a Forgotten Syndrome

Kumar Rakesh , Rifkin Robin , Ehtisham Sarah

Background: The combination of various severe manifestations of hypothyroidism with pseudo muscular hypertrophy is called Kocher Debre Semelaigne syndrome (KDS). KDS is very rare in countries where newborn screening for hypothyroidism is in place. Most of the reports of KDS have come from India and developing countries with only a single report from Europe over last five decades. We present a 7-year-old boy from UK who had short stature and apparent partial lipodystrophy.<...

hrp0094p1-196 | Thyroid B | ESPE2021

Clinical and Molecular Presentation of Congenital Hypothyroidism Caused by Thyroglobulin Gene Mutations

Bakhamis Sarah , AlSagheir Afaf , AlShareef Itizan ,

Background: Congenital hypothyroidism (CH) characterized by a deficient secretion of thyroid hormone in newborn. It is the most common endocrine disease in the children with an incidence rate about 1: 3000 live births in Saudi Arabia. Thyroid dysgenesis and dyshormonogenesis are the most common causes. Thyroid dyshormonogensis commonly inherited as autosomal recessive disorders. Although Thyroglobulin followed by TSHR mutations are the most common genetic defe...

hrp0097rfc12.3 | Thyroid | ESPE2023

Thyroid disorders in childhood cancer survivors treated with 131 I-MIBG, TKIs or immune checkpoint inhibitors: incidence, mechanisms and clinical management – systematic review

Allaert Sarah , Rochtus Anne , Decallonne Brigitte

Background: The thyroid gland is a common unintended target during and after cancer treatment in childhood cancer survivors. However, only a limited number of studies have assessed thyroid adverse events of newer or more selective anticancer drugs. The main objectives of this review are to provide an overview of thyroid disorders in children, treated with 131 I-metaiodobenzylguanidine (131 I-MIBG), tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibi...

hrp0097p1-545 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Challenges in Diagnosing and Managing Paediatric Metastatic Paraganglioma: A Case Report

Baioumi Alaa , Jayne Farndon Sarah , Crowne Elizabeth

Background: Paragangliomas are rare tumours that originate from neural crest cells. Diagnosing and managing patients with paragangliomas pose several challenges.Objective: We investigated whether MECP2 defects are associated with an idiopathic CPP phenotype with or without mild neurodevelopmental abnormalities.Clinical presentation: A 14-year-old female presented with cons...

hrp0097p2-147 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Posterior Sellar Spine - an unusual cause of precocious puberty

Samad Punekar Abdul , Shehab Mostafa , Ehtisham Sarah

A 7 year old girl presented with breast development, mood changes and rapid growth spurt from 6.5 years. Clinically she was tall for her family and had Tanner stage 2 breast development and pubic hair. Bone age was 3 years advanced and pelvic ultrasound demonstrated globular anteverted uterus with endometrial lining and enlargement of the ovaries with follicles. LHRH test confirmed central precocious puberty with peak LH 44mIU/ml and FSH 19mIU/ml, with baseline estradiol of 92...

hrp0095p1-312 | Growth and Syndromes | ESPE2022

Global Increlex® Registry, post-authorisation surveillance registry monitoring the long-term safety and effectiveness of mecasermin in children and adolescents with Severe Primary IGFD (SPIGFD): objectives and study design

Bang Peter , Mazain Sarah , Perrot Valérie , Sert Caroline

Background: Severe primary insulin-like growth factor-1 deficiency (SPIGFD) is a rare growth disorder characterised by severe short stature. Replacement therapy with recombinant human IGF-1 (rhIGF-1; mecasermin [Increlex®]) is currently the only available treatment for children/adolescents with SPIGFD. We describe the methodology of the Global Increlex Patient Registry (NCT00903110), designed to monitor long-term safety and effectiveness of meca...